Allied : Signs Letter of Intent with Evoke Neurosciences to Partner on the Analysis and Treatment of PTSD Patients

Allied Corp. (OTC Pink: ALID) (“Allied”), an international medical cannabis production company focused on creating and providing targeted cannabinoid health solutions, is pleased to announce its signing of a Letter Of Intent (“the LOI”) with Evoke Neurosciences (“Evoke”). Evoke’s eVox System generates an objective and automated report for clinicians and researchers to use as a baseline and to aid diagnosis and facilitate treatment planning for patients living with PTSD. Under the LOI, Allied would employ Evoke’s eVox System to assess the function of the Central and Autonomic Nervous System via EEG, ECG, and Event-Related Potentials (ERPs).

This data is collected via an easy-to-use, FDA-cleared, class 2 medical device that acquires patient data non-invasively in a clinical setting. With the eVox System, clinicians can establish a baseline of the patient’s brain function, monitor treatment effects and measure changes in brain function. Additionally, clinicians who use the eVox System have found that the objective data facilitates a greater buy-in from patients that can lead to increased patient adherence.

This mutually beneficial partnership between Allied and Evoke would be characterized by the following:

Evoke could support Allied’s existing and planned clinical trials by providing pre- and post- treatment measurements of patients’ cognitive functions. The eVox system could be readily deployed for these efforts and Evoke would be able to train staff on how to operate the device to collect data. The eVox System reports would be automatically generated and be accessible via a web portal. Depending on the study objectives, Evoke could develop a custom report. Allied Corp. would publish the results of the clinical trial to further substantiate the utility of EEG, ERPs, and ECG as vital measures (biomarkers).
Allied would develop a commercial package that pairs its therapy products with a pre- and post- treatment eVox assessment. This would help Allied differentiate its products to a clinician target market.
Allied and Evoke could work together to expand their existing marketing efforts with respect to Veterans, PTSD patients and new markets (e.g. Pain management). Evoke has the capability to provide objective measures of PTSD and chronic pain that could be customized for the specific application.
“We are extremely excited to partner with Evoke,” said Calum Hughes, CEO of Allied Corp. “This partnership not only facilitates a greater understanding of PTSD, but it also accelerates the path to treatment for veterans and first responders. We believe that by utilizing the eVox technology, we would accumulate essential data that will aid in further developing a better therapeutic solution.”

About Evoke Neuroscience:
Evoke Neuroscience (www.evokeneuroscience.com) was formed in 2009 with the mission to improve diagnosis and treatment of cognitive disorders with objective, clinically meaningful and easy-to-use products. Primary and specialty care physicians can use eVox® to acquire objective and stable biomarkers of brain function in-office via a non-invasive procedure, in order to aid in the diagnosis of cognitive and mental disorders. Doctors should use their professional judgment in determining when the eVox® System is appropriate to aid in diagnosis.

© Copyright 2019 — Evoke Neuroscience, Inc.

Terms & Conditions | Privacy Policy | Interest-based Ads


ISO 13485 CertifiedThe eVox system is a Class II medical device that has received Section 510(K) clearance from the FDA. It is intended for the acquisition, display, and storage, of electrical activity of a patient’s brain including electroencephalograph (EEG) and event-related potentials (ERP) obtained by placing two or more electrodes on the head to aid in diagnosis.

Log in with your credentials

Forgot your details?